Rondon, E., & Venkataraman, R. (2005). Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels. BioMed Central.
Styl ChicagoRondon, Eliseo, a Ramesh Venkataraman. Afelimomab Led to a Modest Mortality Benefit in Patients With Severe Sepsis and Elevated Interleukin-6 Levels. BioMed Central, 2005.
Citace podle MLARondon, Eliseo, a Ramesh Venkataraman. Afelimomab Led to a Modest Mortality Benefit in Patients With Severe Sepsis and Elevated Interleukin-6 Levels. BioMed Central, 2005.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..